U.S. Stock Market Midday Update
Picard Medical fell 11.15%. Based on recent key news:
<ol>
<li>
On June 2, Picard Medical announced the replacement of its Chief Financial Officer, appointing Georgina Smith as Chief Accounting Officer. This move aims to strengthen financial management, and the market is optimistic about its future development, with the stock price rising over 10% in after-hours trading.
</li>
<li>
On June 2, the company's subsidiary SynCardia Systems LLC continued to advance the research and development of artificial heart technology, further boosting market confidence, with the stock price rising 111% in pre-market trading.
</li>
<li>
On June 3, Picard Medical's stock price reported $0.2991 in after-hours trading, an increase of over 10%. The market is optimistic about the company's financial management and technology development.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Medtronic rose 4.25%. Based on recent news,
<ol>
<li>
On June 3, Medtronic released its fourth-quarter financial report, with revenue and adjusted earnings per share exceeding Wall Street expectations, driving the stock price up. The report showed Medtronic's fourth-quarter revenue was $9.81 billion, higher than the market expectation of $9.63 billion, with adjusted earnings per share of $1.55, slightly above analysts' expectations of $1.54. Medtronic's stock price rose 2.8% in pre-market trading.
</li>
<li>
On June 3, Medtronic announced the acquisition of SPR Therapeutics, further enhancing its neuromodulation business. The acquisition amount was $650 million, marking Medtronic's third major acquisition in 2026, demonstrating the company's proactive stance in expanding its business.
</li>
<li>
On June 4, Medtronic submitted a new regulatory application to the FDA, aiming to expand the indications for its Hugo robotic-assisted surgical system. This move indicates Medtronic's intention to challenge Intuitive Surgical's dominance in the robotic surgery market, and investors are optimistic, driving the stock price up. The overall industry performed well, with significant policy support.
</li>
</ol>
Abbott rose 3.60%. Based on recent news,
<ol>
<li>
On June 3, Insulet Corporation announced that the enhanced features of its Omnipod 5 automated insulin delivery system's new algorithm have been fully launched in the U.S. and are compatible with Abbott's FreeStyle Libre 3 Plus sensor. This integration increases users' sensor options, enhancing the system's automation performance and effectiveness, driving Abbott's stock price up.
</li>
<li>
On June 3, Insulet Corporation stated that the new algorithm adds a target blood glucose option of 100 mg/dL, allowing for more refined personalization settings, helping users experience fewer interruptions during prolonged high blood glucose events while maintaining operation in automatic mode. This news further boosts market confidence in Abbott's products
On June 3rd, Insulet Corporation began shipping the new algorithm-compatible Pods to U.S. retail channels ahead of schedule, with users receiving wireless software updates via the Omnipod 5 controller or mobile app. This move accelerates the market promotion of new technology, benefiting Abbott's stock price. Innovations in diabetes management technology are driving market demand.
</li>
</ol>
Boston Scientific rose 1.81%. Based on recent key news:
<ol>
<li>
On June 2nd, Canaccord Genuity lowered Boston Scientific's target price from $71 to $70, reflecting the market's cautious attitude towards its future growth.
</li>
<li>
On June 4th, Truist Securities lowered Boston Scientific's target price from $85 to $64, further exacerbating market concerns about its profitability.
</li>
<li>
On June 2nd, Boston Scientific was seen attempting to bolster investor confidence through stock buybacks amid wavering investor sentiment, demonstrating the company's response strategy in the face of market uncertainty. The medical device industry is experiencing active innovation, with increased market volatility.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Intuitive Surgical rose 2.03%. Based on recent key news:
<ol>
<li>
On June 4th, Medtronic announced a new regulatory filing for its robotic surgery system, indicating its intent to challenge Intuitive Surgical's market position. This move sparked investor optimism about Medtronic's advanced surgical technology, which could pose a threat to Intuitive Surgical's market share.
</li>
<li>
On June 2nd, Intuitive Surgical's Senior Vice President Jeddi Iman exercised options and sold 5,625 shares at a transaction price of $420.55 per share. This insider trading may raise market concerns about internal confidence in the company.
</li>
<li>
On June 2nd, Motley Fool recommended Intuitive Surgical as a long-term investment choice, emphasizing its potential and performance in the market. Competition in the robotic surgery market is intensifying, and investors should pay attention
</li>
</ol>

Picard Medical fell 11.15%; Medtronic rose 4.25%, with a transaction volume of USD 764 million; Abbott rose 3.60%, with a transaction volume of USD 733 million; Boston Scientific rose 1.81%, with a transaction volume of USD 653 million; Intuitive Surgical rose 2.03%, with a market value of USD 147.2 billion

Price Alert

Picard Medical

U.S. stock market midday update: Picard Medical down 11.15%, change of CFO and favorable R&D cannot hide the selling pressure